Medicine and Dentistry
Rituximab
61%
Ibrutinib
60%
Arm
50%
Overall Survival
50%
Diseases
41%
Progression Free Survival
39%
Quality of Life
26%
Positron Emission Tomography
25%
Adverse Event
25%
B-Cell Chronic Lymphocytic Leukemia
24%
Diffuse Large B-Cell Lymphoma
23%
Acute Myeloid Leukemia
22%
MALT Lymphoma
22%
Whole Brain Radiotherapy
18%
Survival Rate
17%
Hazard Ratio
17%
Cytarabine
17%
Primary Central Nervous System Lymphoma
16%
Event Free Survival
16%
Carmustine
15%
Monotherapy
14%
Teniposide
14%
Etoposide
13%
Bruton Tyrosine Kinase Inhibitor
13%
Cancer
13%
Clinical Trial
13%
Drug Megadose
13%
Randomized Controlled Trial
12%
Idarubicin
12%
Lymphocytic Lymphoma
12%
Atrial Fibrillation
12%
Prognostic Factor
12%
Prednisolone
12%
International Prognostic Index
12%
Flow Cytometry
11%
Methotrexate
11%
B Cell
11%
Peripheral T-Cell Lymphoma
11%
Carboplatin
11%
Stem Cell Therapy
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Yttrium 90
11%
Immunologic Function
11%
Central Nervous System
11%
Palifermin
11%
Gastrointestinal Toxicity
11%
Acute Myelogenous Leukemia
11%
Biological Marker
11%
Chronic Kidney Disease
11%
Diarrhea
11%
Pharmacology, Toxicology and Pharmaceutical Science
Zanubrutinib
100%
Waldenstroem macroglobulinemia
56%
Adverse Event
41%
Ibrutinib
38%
Progression Free Survival
34%
Chemotherapy
34%
Rituximab
33%
Acute Myeloid Leukemia
33%
Diseases
25%
Bruton Tyrosine Kinase Inhibitor
24%
Chronic Lymphatic Leukemia
23%
Diffuse Large B Cell Lymphoma
23%
Overall Survival
20%
Lymphocytic Lymphoma
15%
Neutropenia
15%
Monotherapy
14%
Etoposide
14%
Idarubicin
13%
Atrial Fibrillation
13%
Leukemia
12%
Remission
12%
Cytarabine
12%
Diarrhea
12%
Placebo
12%
Mantle Cell Lymphoma
12%
Clinical Trial
12%
Bruton Tyrosine Kinase
11%
Ifosfamide
11%
Sorafenib
11%
Protein Tyrosine Kinase
11%
Placebo-Controlled Study
11%
Primary Central Nervous System Lymphoma
11%
Palifermin
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Carboplatin
11%
Yttrium 90
11%
Gastrointestinal Toxicity
11%
Bleeding
10%
Infection
9%
Anthracycline
9%
Tolerability
8%
Survival Rate
8%
Methotrexate
7%
Motor Dysfunction
6%
Malignant Neoplasm
6%
Oral Mucositis
6%
Anemia
6%
Gemtuzumab Ozogamicin
5%
Azacitidine
5%
Cancer Registry
5%
Immunology and Microbiology
Rituximab
55%
B Cell
34%
Macroglobulinemia
33%
Arm
30%
Overall Survival
25%
Positron Emission Tomography
22%
Progression Free Survival
21%
Event Free Survival
18%
Hematopoietic Cell
14%
Drug Megadose
13%
Prednisolone
12%
T Cell
12%
Methotrexate
11%
Central Nervous System
11%
Myeloid
11%
Ibritumomab Tiuxetan
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Stem Cell Transplantation
11%
Sorafenib
11%
Multiple Sclerosis
11%
Autologous Stem Cell Transplantation
11%
Gemtuzumab Ozogamicin
11%
Drug Screening
11%
Cell Transplantation
11%
Bruton Tyrosine Kinase
11%
Lymphocyte
11%
Tyrosine
11%
Programmed Cell Death
11%
Survival Rate
10%
Wild Type
10%
MYD88
7%
Myeloid Differentiation
5%